188 related articles for article (PubMed ID: 2028562)
1. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis.
de Boer EC; de Jong WH; van der Meijden AP; Steerenberg PA; Witjes F; Vegt PD; Debruyne FM; Ruitenberg EJ
Urol Res; 1991; 19(1):45-50. PubMed ID: 2028562
[TBL] [Abstract][Full Text] [Related]
2. Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin.
De Boer EC; De Jong WH; Van Der Meijden AP; Steerenberg PA; Witjes JA; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1991; 33(6):411-6. PubMed ID: 1878894
[TBL] [Abstract][Full Text] [Related]
3. Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guerin.
De Boer EC; De Jong WH; Steerenberg PA; Van der Meijden AP; Aarden LA; Debruyne FM; Ruitenberg EJ
In Vivo; 1991; 5(6):671-7. PubMed ID: 1810454
[TBL] [Abstract][Full Text] [Related]
4. Effects of isoniazid (INH) on the BCG-induced local immune response after intravesical BCG therapy for superficial bladder cancer.
Stassar MJ; Vegt PD; Steerenberg PA; van der Meijden AP; Meiring HD; Dessens-Kroon M; Geertzen HG; den Otter W
Urol Res; 1994; 22(3):177-84. PubMed ID: 7992464
[TBL] [Abstract][Full Text] [Related]
5. Soluble urinary CD14 after intravesical bacille Calmette-Guérin immunotherapy for carcinoma in situ.
Jackson AM; Lien E; Alexandroff AB; Prescott S; Espevik T; James K; Selby PJ; Sundan A
Br J Urol; 1997 Nov; 80(5):766-71. PubMed ID: 9393300
[TBL] [Abstract][Full Text] [Related]
6. Local immune responses after intravesical BCG treatment for carcinoma in situ.
el-Demiry MI; Smith G; Ritchie AW; James K; Cumming JA; Hargreave TB; Chisholm GD
Br J Urol; 1987 Dec; 60(6):543-8. PubMed ID: 3501324
[TBL] [Abstract][Full Text] [Related]
7. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
8. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis.
Jackson AM; Ivshina AV; Senko O; Kuznetsova A; Sundan A; O'Donnell MA; Clinton S; Alexandroff AB; Selby PJ; James K; Kuznetsov VA
J Urol; 1998 Mar; 159(3):1054-63. PubMed ID: 9474231
[TBL] [Abstract][Full Text] [Related]
10. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
11. HLA-DR expression by high grade superficial bladder cancer treated with BCG.
Prescott S; James K; Busuttil A; Hargreave TB; Chisholm GD; Smyth JF
Br J Urol; 1989 Mar; 63(3):264-9. PubMed ID: 2522806
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulation in the urinary bladder by local application of Nocardia rubra cell wall skeleton preparation (Rubratin) for superficial bladder cancer immunotherapy--a phase I/II study.
de Reijke TM; de Boer EC; Schamhart DH; Kurth KH
Urol Res; 1997; 25(2):117-20. PubMed ID: 9144878
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic problems of urine cytology on initial follow-up after intravesical immunotherapy with Calmette-Guérin bacillus for superficial bladder cancer.
Mack D; Frick J
Urol Int; 1994; 52(4):204-7. PubMed ID: 8030167
[TBL] [Abstract][Full Text] [Related]
14. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
[TBL] [Abstract][Full Text] [Related]
15. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guerin therapy for superficial bladder cancer.
Fleischmann JD; Toossi Z; Ellner JJ; Wentworth DB; Ratliff TL; Imbembo AL
Cancer; 1989 Oct; 64(7):1447-54. PubMed ID: 2789094
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells.
Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C
J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930
[TBL] [Abstract][Full Text] [Related]
17. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms.
Prescott S; Jackson AM; Hawkyard SJ; Alexandroff AB; James K
Clin Infect Dis; 2000 Sep; 31 Suppl 3():S91-3. PubMed ID: 11010831
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress of red blood cells during Bacillus Calmette-Guerin intravesical instillations.
Mitropoulos D; Deliconstantinos G; Zervas A; Giannopoulos A; Kyriakou G; Dimopoulos C
In Vivo; 2000; 14(6):721-4. PubMed ID: 11204488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
